Fasting Clinical Trial
Official title:
The Effect of Modulating Hepatic Glycogen Content on Hepatic Fat Oxidation
Excessive fat in the liver is associated with impairments in metabolic health. Low levels of
DNL and high levels of hepatic fat oxidation are considered to be protective.
A decrease in glycogen stores has been causally linked to improved whole body fat oxidation.
Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low
hepatic glycogen stores. Next to hepatic fat oxidation, DNL may be influenced by hepatic
glycogen stores. Some studies have shown that prolongation of fasting time lowers hepatic
glycogen content. It is therefore hypothesized that prolonging fasting time will lower
glycogen content and thereby increases fat oxidation and decreases DNL in the liver. To this
end, hepatic fat oxidation (plasma marker beta-hydroxybutyrate), de novo lipogenesis, hepatic
glycogen content and intrahepatic fat content, will be measured upon a short overnight fast
and an extended overnight fast in 13 overweight/obese subjects with hepatic steatosis.
Rationale:
Excessive fat in the liver is associated with impairments in metabolic health. Hepatic lipid
storage can originate from several metabolic pathways, including de novo lipogenesis (DNL).
On the other hand, there are several metabolic pathways that can decrease hepatic fat
storage, such as hepatic fat oxidation. Therefore, low levels of DNL and high levels of
hepatic fat oxidation are considered to be protective.
A decrease in glycogen stores has been causally linked to improved whole body fat oxidation.
Also on an organ level, it is suggested that hepatic fat oxidation is stimulated by low
hepatic glycogen stores. Furthermore, whole body glycogen levels were also linked to DNL and
in situations with increased whole body glycogen levels in animal models rates of DNL were
also high. Therefore, next to hepatic fat oxidation, DNL may be influenced by hepatic
glycogen stores.
Some studies have shown that prolongation of fasting time lowers hepatic glycogen content. It
is therefore hypothesized that prolonging fasting time will lower glycogen content and
thereby increases fat oxidation and decreases DNL in the liver.
Objective:
The primary objective of this study is to investigate to what extent hepatic fat oxidation
can be stimulated by lowering hepatic glycogen content during a prolonged overnight fast.
The secondary objective is to investigate whether reductions in hepatic glycogen content are
also accompanied by a decrease in DNL. In addition, the metabolic response to a meal
(metabolites related to energy metabolism and substrate oxidation) will be studied upon
prolonged overnight fasting. Finally, it will be studied whether reducing hepatic glycogen
content by prolonged overnight fasting during a few consecutive days lowers intrahepatic fat
storage and changes hepatic fat composition.
Study design:
This is a randomized cross-over study.
Study population:
Thirteen healthy overweight/obese males and postmenopausal females, aged between 45-75 years
and BMI between 27-38 kg/m2, with liver fat content ≥ 5% will participate in the study. To be
able to include enough people with a liver fat content ≥5%, around 27 participants are
expected to be screened for liver fat. When liver fat content is <5%, participants will not
be included in the study after determination of liver fat content.
Main study parameters/endpoints:
The primary study outcome is hepatic fat oxidation measured as plasma beta-hydroxybutyrate
(BHB) levels, which will be measured before and after one night adherence to the fasting
protocols. The secondary study outcome is DNL as determined by stable isotope techniques and
will also be measured after one night adherence to the fasting protocols. Other study
outcomes include hepatic glycogen content, substrate oxidation and plasma metabolites related
to energy metabolism (measured before and after one night adherence to the fasting protocols)
and intrahepatic fat content and composition (measured after 6 days of adherence to the
fasting protocols).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03754920 -
Prolonged Fasting With Meditation and Mild Physical Exercise
|
N/A | |
Completed |
NCT05272332 -
Gastric Ultrasound Prior to Extubation
|
||
Completed |
NCT04247464 -
Short-term Fasting as an Enhancer of Chemotherapy: Pilot Clinical Study on Colorectal Carcinoma Patients
|
N/A | |
Completed |
NCT01067001 -
Minocycline HCl Extended Release Tablets 135 mg Oral Bioequivalence Study
|
N/A | |
Completed |
NCT00757094 -
Safety and Feasibility of Fasting While Receiving Chemotherapy
|
N/A | |
Completed |
NCT01506713 -
Bioequivalence Study of Clopidogrel Tablets 75 mg of Dr. Reddy's Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT04514380 -
Effect of Drinking Carbohydrate-containing Fluids on Gastric Residual Volume in Elderly Patients
|
||
Completed |
NCT05756868 -
The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior
|
N/A | |
Completed |
NCT05134207 -
The Effect of Oral Carbohydrate Solution on Anxiety and Comfort in Patients Undergoing Hip Arthroplasty
|
N/A | |
Completed |
NCT05031598 -
Long-term Fasting: Multi-system Adaptations in Humans
|
N/A | |
Recruiting |
NCT04501393 -
Recommended Clear Fluid Intake Volume at 2 Hours Prior to Esophagogastroduodenoscopy for Adult Patients
|
N/A | |
Enrolling by invitation |
NCT04027478 -
Can Fasting Decrease the Side Effects of Chemotherapy?
|
N/A | |
Completed |
NCT05219136 -
Improve the Comfort, Safety and Quality of Upper Endoscopy by a Modified Fasting Protocol
|
N/A | |
Recruiting |
NCT04625608 -
Effect of Premedicant Oral Paracetamol on Gastric Volume and pH
|
Phase 4 | |
Not yet recruiting |
NCT02562638 -
Pre-Procedural Fasting in Cardiac Intervention
|
N/A | |
Completed |
NCT01954836 -
Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial
|
N/A | |
Completed |
NCT01949987 -
Does Oral Intake Decreases Postoperative Pain Score in Children
|
N/A | |
Completed |
NCT01746719 -
Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition
|
Phase 1 | |
Completed |
NCT01721187 -
Satiety Effects on the Neural Valuation of Food
|
N/A | |
Completed |
NCT01713647 -
Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions
|
Phase 1 |